BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31292535)

  • 1. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.
    Brar G; Blais EM; Joseph Bender R; Brody JR; Sohal D; Madhavan S; Picozzi VJ; Hendifar AE; Chung VM; Halverson D; Mikhail S; Matrisian LM; Rahib L; Petricoin E; Pishvaian MJ
    Br J Cancer; 2019 Jul; 121(3):264-270. PubMed ID: 31292535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.
    Ferguson MD; Dong L; Wan J; Deneve JL; Dickson PV; Behrman SW; Shibata D; Martin MG; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):285-291. PubMed ID: 29427136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance.
    Schleger C; Verbeke C; Hildenbrand R; Zentgraf H; Bleyl U
    Mod Pathol; 2002 Apr; 15(4):462-9. PubMed ID: 11950922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
    Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP
    Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer.
    Drosos Y; Escobar D; Chiang MY; Roys K; Valentine V; Valentine MB; Rehg JE; Sahai V; Begley LA; Ye J; Paul L; McKinnon PJ; Sosa-Pineda B
    Sci Rep; 2017 Sep; 7(1):11144. PubMed ID: 28894253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
    Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATM whole gene deletion in an Italian family with hereditary pancreatic cancer: Challenges to cancer risk prediction associated with an 11q22.3 microdeletion.
    Arts HH; Lynch L; Grafodatskaya D; Eng B; Malloy L; Duck J; White R; Woodside C; Bell K; Zbuk KM; McCready E
    Cancer Genet; 2020 Jan; 240():1-4. PubMed ID: 31671381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonality of localized and metastatic prostate cancer.
    Boutros PC; Fraser M; van der Kwast T; Bristow RG
    Curr Opin Urol; 2016 May; 26(3):219-24. PubMed ID: 26885716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-depth sequencing of paired primary and metastatic tumours: Implications for personalised medicine.
    Grellety T; Lucchesi C; Hostein I; Auzanneau C; Khalifa E; Soubeyran I; Italiano A
    Eur J Cancer; 2017 Oct; 84():250-256. PubMed ID: 28841542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.
    Amato E; Mafficini A; Hirabayashi K; Lawlor RT; Fassan M; Vicentini C; Barbi S; Delfino P; Sikora K; Rusev B; Simbolo M; Esposito I; Antonello D; Pea A; Sereni E; Ballotta M; Maggino L; Marchegiani G; Ohike N; Wood LD; Salvia R; Klöppel G; Zamboni G; Scarpa A; Corbo V
    J Pathol; 2019 Jan; 247(1):123-134. PubMed ID: 30306561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
    Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
    Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies.
    Le Large TYS; Bijlsma MF; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
    Semin Cancer Biol; 2017 Jun; 44():153-169. PubMed ID: 28366542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
    Kim EY; Cho EN; Park HS; Kim A; Hong JY; Lim S; Youn JP; Hwang SY; Chang YS
    BMC Cancer; 2016 Jan; 16():27. PubMed ID: 26782967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition.
    Russell R; Perkhofer L; Liebau S; Lin Q; Lechel A; Feld FM; Hessmann E; Gaedcke J; Güthle M; Zenke M; Hartmann D; von Figura G; Weissinger SE; Rudolph KL; Möller P; Lennerz JK; Seufferlein T; Wagner M; Kleger A
    Nat Commun; 2015 Jul; 6():7677. PubMed ID: 26220524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review.
    Sherwood J; Dearden S; Ratcliffe M; Walker J
    J Exp Clin Cancer Res; 2015 Sep; 34(1):92. PubMed ID: 26338018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.
    Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M
    BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.